Advances in therapeutic approaches to ulcerative colitis and crohn’s disease

Abstract

Advances (from 2004 to 2006) in the use of conventional agents include the molecular mechanisms of action, which have implications for monitoring (azathioprine and thioguanosine triphosphate) and chemoprevention (mesalamine and peroxisome proliferator activated receptor gamma). Advances in biotherapy include new data on monoclonal antibodies (infliximab in ulcerative colitis, adalimumab, certolizumab pegol, fontolizumab, selective anti-adhesion molecules, and others), antisense oligonucleotides, the development of small molecules, and cell-gene therapy (including helminth ova, leukocytapheresis, stem cell transplantation, and probiotic intestinal mucosal delivery systems). However, management of inflammatory bowel disease is about more than drug therapy, dose, and timing. The goals remain induction of remission, limitation of side effects, modification of the pattern of disease, and avoidance of complications. With the cost and complexity of biotherapy, inflammatory bowel disease is emerging as a specific subspecialty.

Does the Gut Microbiota Influence Immunity and Inflammation in Multiple Sclerosis Pathophysiology?

“…The clinical effects of probiotics are beneficial and activities of the specific strain cannot be transferred to another strain of the same species. Clinical observations indicate that the probiotic strains may be potentially useful in the treatment of inflammatory diseases [37]. …”

European evidence based consensus on the diagnosis and management of Crohn's disease: current management

“…52 Limited comment is made because results have been presented or published after the consensus meeting. Adalimumab is a fully human anti-TNF monoclonal antibody given by subcutaneous injection.…”

The JNK Inhibitor XG-102 Protects against TNBS-Induced Colitis

“…Moreover, JNK act as transducers of endoplasmatic reticulum (ER) stress [3], [9], [11], [15], [16], [17], [18], [19]. Therefore, inhibition of JNKs emerges as a promising therapeutic principle in various inflammatory diseases including IBD [3], [20], [21], [22] and was previously shown to counteract colorectal tumorigenesis [23], [24] that occurs in the cause of chronic IBD.…”